At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNTM Quantum Biopharma Ltd.
Post-Mkt 05-11 17:50:34 EDT
5.06
+0.18
+3.69%
盘后5.06
+0.000.00%
17:18 EDT
High5.34Low4.60Vol172.75K
Open4.79D1 Closing4.88Amplitude15.16%
Mkt Cap29.50MTradable Cap26.55MTotal Shares5.83M
T/O855.73KT/O Rate3.29%Tradable Shares5.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Dow Jones  ·  05-07
Press Release: Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
Quantum BioPharma Provides Corporate Update
GlobeNewswire  ·  04-28
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
GlobeNewswire  ·  04-22
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
GlobeNewswire  ·  04-02
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
GlobeNewswire  ·  04-01
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM
Reuters  ·  03-30
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
GlobeNewswire  ·  03-30
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
Quantum Biopharma Provides Corporate Update
GlobeNewswire  ·  03-28
Quantum Biopharma Provides Corporate Update
Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status
Dow Jones  ·  03-27
Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Benzinga  ·  03-27
Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
GlobeNewswire  ·  03-26
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
GlobeNewswire  ·  03-23
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
Press Release: Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
Dow Jones  ·  03-21
Press Release: Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
Quantum BioPharma Provides Corporate Update
GlobeNewswire  ·  03-12
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Provides Corporate Update
GlobeNewswire  ·  03-11
Quantum BioPharma Provides Corporate Update
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
GlobeNewswire  ·  2025-12-23
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
GlobeNewswire  ·  2025-12-20
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
GlobeNewswire  ·  2025-12-01
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
GlobeNewswire  ·  2025-11-28
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
GlobeNewswire  ·  2025-11-26
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Introduction

Company Name.
Quantum Biopharma Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
Issue price:
--